Financial support from Utah alum Pierre Lassonde and his family foundation are pivotal to the program’s growth ...

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...

'Planet C: Home Race' gave birth to the global boy group 'Modyssey (MODYSSEY)', and the final debut members were confirmed as ...

Korean automakers unveil 16 new models as EVs and SUVs surge in 2026 Kama predicts 16 new domestic models this year as EV and ...

After a year in which expansion and slowdown coexisted across Korean pop culture, 2026 is shaping up to be a potential ...

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and ...

The year 2025 will be etched in Malawi’s history as the year of the great return. The political landscape shifted by the ...

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

Angelo Stiller and Adam Wharton are among the leading candidates, although the Chamartín club traditionally keeps a close eye ...

FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...